Grandfield & Dodd Portfolio holdings
Grandfield & Dodd is an independently owned investment counsel firm that builds portfolios of individual stocks and bonds for individuals, families and trusts. Cheryl Grandfield, a former partner at Brundage, Story & Rose, started it in 2001 with Richard Dodd, who had been a senior portfolio manager of tax-exempt bonds at The Bank of New York, and James Samuels. They saw a gap as investment managers moved toward standardised pooled products, and aimed at clients who preferred owning individual securities directly. On stocks, the firm looks at companies as a business owner would and favours industry leaders, while keeping its holdings spread across industries and securities. Its bond holdings lean toward higher quality and shorter maturities, which limits how far prices swing when interest rates change.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$4.72M |
| 2 |
A.O. Smith
AOS
|
+$2.6M |
| 3 |
Carlisle Companies
CSL
|
+$2.36M |
| 4 |
Veralto
VLTO
|
+$1.71M |
| 5 |
Autodesk
ADSK
|
+$1.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Applied Materials
AMAT
|
+$3.25M |
| 2 |
Diageo
DEO
|
+$2.8M |
| 3 |
Johnson Controls International
JCI
|
+$2.66M |
| 4 |
GE Aerospace
GE
|
+$1.62M |
| 5 |
Analog Devices
ADI
|
+$1.52M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.78% |
| 2 | Industrials | 19.46% |
| 3 | Healthcare | 14.71% |
| 4 | Financials | 8.44% |
| 5 | Materials | 7.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Fastenal
FAST
$63.3B
| $2.59M | 0.14% |
52,228
| – | – |
2016 Q3
40 quarters
|
|
77
State Street SPDR S&P 500 ETF Trust
SPY
$800B
| $2.55M | 0.14% |
3,349
-111
| -3% | -$84.3K |
2019 Q1
30 quarters
|
|
78
Incyte
INCY
$24.7B
| $2.55M | 0.14% |
20,980
+158
| +0.8% | +$19.3K |
2013 Q4
51 quarters
|
|
79
Neurocrine Biosciences
NBIX
$16.9B
| $2.36M | 0.13% |
16,649
-10
| -0.1% | -$1.61K |
2017 Q1
38 quarters
|
|
80
Emerson Electric
EMR
$91.3B
| $2.34M | 0.12% |
15,095
| – | – |
2013 Q2
53 quarters
|
|
81
iShares Core S&P 500 ETF
IVV
$875B
| $2.32M | 0.12% |
3,030
| – | – |
2020 Q1
26 quarters
|
|
82
Eli Lilly
LLY
$1.29T
| $2.21M | 0.12% |
1,912
-123
| -6% | -$145K |
2013 Q2
53 quarters
|
|
|
83
Carlisle Companies
CSL
$15.3B
| $2.19M | 0.12% |
+6,797
| New | +$2.36M |
2026 Q3
0 quarters
|
|
84
NVIDIA
NVDA
$3.93T
| $2.18M | 0.12% |
9,526
-240
| -2% | -$51.5K |
2022 Q4
15 quarters
|
|
85
Nutrien
NTR
$33.8B
| $2.17M | 0.12% |
30,960
| – | – |
2018 Q1
34 quarters
|
|
86
Vanguard FTSE All-World ex-US ETF
VEU
$66.6B
| $2.01M | 0.11% |
24,220
-235
| -1% | -$19.7K |
2015 Q4
43 quarters
|
|
87
PepsiCo
PEP
$198B
| $1.96M | 0.1% |
15,465
| – | – |
2013 Q2
53 quarters
|
|
88
Vanguard Health Care ETF
VHT
$21.1B
| $1.92M | 0.1% |
6,090
| – | – |
2020 Q3
24 quarters
|
|
|
89
Veralto
VLTO
$28.8B
| $1.92M | 0.1% |
20,392
+17,926
| +727% | +$1.71M |
2023 Q4
11 quarters
|
|
90
iShares Russell 1000 ETF
IWB
$47.8B
| $1.88M | 0.1% |
4,523
| – | – |
2022 Q1
18 quarters
|
|
91
Vanguard S&P 500 ETF
VOO
$1.04T
| $1.83M | 0.1% |
2,611
-600
| -19% | -$419K |
2014 Q1
50 quarters
|
|
92
Zimmer Biomet
ZBH
$19.5B
| $1.82M | 0.1% |
20,823
+9,284
| +80% | +$880K |
2013 Q2
53 quarters
|
|
93
Adobe
ADBE
$94.6B
| $1.74M | 0.09% |
7,237
-110
| -1% | -$27.5K |
2013 Q2
53 quarters
|
|
94
Colgate-Palmolive
CL
$79.2B
| $1.7M | 0.09% |
19,914
-150
| -0.7% | -$13.6K |
2013 Q2
53 quarters
|
|
95
Ionis Pharmaceuticals
IONS
$4.84B
| $1.67M | 0.09% |
37,396
+319
| +0.9% | +$18.1K |
2015 Q4
43 quarters
|
|
96
Exelixis
EXEL
$16.8B
| $1.58M | 0.08% |
27,029
-80
| -0.3% | -$4.46K |
2024 Q3
8 quarters
|
|
97
Philip Morris
PM
$310B
| $1.51M | 0.08% |
7,907
+1,042
| +15% | +$197K |
2013 Q2
53 quarters
|
|
98
AbbVie
ABBV
$521B
| $1.5M | 0.08% |
5,744
| – | – |
2013 Q2
53 quarters
|
|
99
Automatic Data Processing
ADP
$122B
| $1.47M | 0.08% |
5,704
| – | – |
2013 Q2
53 quarters
|
|
100
Abbott
ABT
$188B
| $1.46M | 0.08% |
14,820
| – | – |
2013 Q2
53 quarters
|
|
Similar funds
Grandfield & Dodd's Q3 2026 Portfolio in Review
As of Q3 2026, Grandfield & Dodd held 223 positions worth $1.87B, down 1.7% from $1.91B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Grandfield & Dodd's Q3 2026 filing shows 6 new, 53 increased, 70 reduced and 7 closed positions. Its largest new stake was Carlisle Companies: 6,797 shares worth $2.19M. The largest sale was Applied Materials, an estimated $3.25M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 32% a quarter earlier, followed by Industrials and Healthcare.
- Grandfield & Dodd's largest Q3 2026 buy was Carlisle Companies: 6,797 shares worth $2.19M.
- Grandfield & Dodd added most to Boeing in Q3 2026, an estimated $4.72M increase.
- Grandfield & Dodd's biggest Q3 2026 reduction was Applied Materials, cutting an estimated $3.25M.
- Grandfield & Dodd fully exited Omnicom Group in Q3 2026, selling an estimated $268K.
- Grandfield & Dodd's ten largest holdings make up 39% of its $1.87B portfolio in Q3 2026.
- Grandfield & Dodd opened 6 new positions and closed 7 in Q3 2026.
- Grandfield & Dodd's portfolio value fell 1.7% quarter-over-quarter to $1.87B.
Based on Grandfield & Dodd's 13F filing for Q3 2026, filed 29 Oct 2026.